{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:37:49Z","timestamp":1787009869757,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Myositis, or idiopathic inflammatory myopathy, is an overarching concept that includes dermatomyositis, polymyositis, immune-mediated necrotizing myopathy and the antisynthetase syndrome. Glucocorticoids are still considered the mainstay of treatment of myositis but some patients require add-on immunosuppressive therapy because of insufficient response to glucocorticoids, relapses when glucocorticoids are tapered, or because they incur glucocorticoid-related side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>The goal of this article was to review (PubMed search from January 2019 through June 2020) the efficacy and safety of standard and novel agents used in adult dermatomyositis, polymyositis, immune-mediated necrotizing myopathy and the antisynthetase syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Established therapies beyond glucocorticoids continue to have a major role in managing patients with myositis. In addition, novel agents are being tried for refractory manifestations of myositis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000745","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T17:08:00Z","timestamp":1599239280000},"page":"523-527","source":"Crossref","is-referenced-by-count":17,"title":["Up-to-date treatment and management of myositis"],"prefix":"10.1097","volume":"32","author":[{"given":"Nicol\u00f2","family":"Pipitone","sequence":"first","affiliation":[{"name":"SC di Reumatologia, Dipartimento Medicina Interna e Specialit\u00e0 Mediche, Azienda Unit\u00e0 Sanitaria Locale di Reggio Emilia - Istituto di Ricerca e Cura a Carattere Scientifico, Reggio Emilia-Romagna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[{"name":"SC di Reumatologia, Dipartimento Medicina Interna e Specialit\u00e0 Mediche, Azienda Unit\u00e0 Sanitaria Locale di Reggio Emilia - Istituto di Ricerca e Cura a Carattere Scientifico, Reggio Emilia-Romagna"},{"name":"Universit\u00e0 degli Studi di Modena e Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11926-015-0548-6","article-title":"Immune-mediated necrotizing myopathy: update on diagnosis and management","volume":"17","author":"Basharat","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/1744666X.2018.1491307","article-title":"Treatment of inflammatory myopathies","volume":"14","author":"Pipitone","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","article-title":"Azathioprine with prednisone for polymyositis. A controlled, clinical trial","volume":"92","author":"Bunch","year":"1980","journal-title":"Ann Intern Med"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/rheumatology\/39.1.7","article-title":"Treatment and investigation of idiopathic inflammatory myopathies","volume":"39","author":"Lundberg","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/030097400750001897","article-title":"Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis","volume":"29","author":"Vencovsky","year":"2000","journal-title":"Scand J Rheumatol"},{"key":"R6-20230829","first-page":"858","article-title":"Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome","volume":"37","author":"Casal-Dominguez","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1586\/17512433.2016.1136561","article-title":"Current pharmacological treatment of idiopathic inflammatory myopathies","volume":"9","author":"Fasano","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ncl.2014.04.007","article-title":"Idiopathic inflammatory myopathies","volume":"32","author":"Dimachkie","year":"2014","journal-title":"Neurol Clin"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00393-018-0471-0","article-title":"Treatment of adult idiopathic inflammatory myopathies with conventional immunosuppressive drugs: results of a retrospective study","volume":"78","author":"Keyser","year":"2019","journal-title":"Z Rheumatol"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10067-018-4294-9","article-title":"Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy","volume":"38","author":"Hanaoka","year":"2019","journal-title":"Clin Rheumatol"},{"key":"R11-20230829","first-page":"740","article-title":"Tacrolimus combined with corticosteroids effectively improved the outcome of a cohort of patients with immune-mediated necrotising myopathy","volume":"37","author":"Feng","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"R12-20230829","doi-asserted-by":"crossref","DOI":"10.5070\/D3256044451","article-title":"Low-dose naltrexone: a unique treatment for amyopathic dermatomyositis","volume":"25","author":"Manudhane","year":"2019","journal-title":"Dermatol Online J"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","article-title":"Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib","volume":"58","author":"Moghadam-Kia","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4236\/ojra.2020.101005","article-title":"Tofacitinib as a treatment for refractory dermatomyositis: a case report","volume":"10","author":"Shinjo","year":"2020","journal-title":"Open J Rheumatol Autoimmune Dis"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","article-title":"Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - a report of two cases","volume":"100","author":"Wendel","year":"2019","journal-title":"J Autoimmun"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","article-title":"Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application","volume":"10","author":"Danieli","year":"2011","journal-title":"Autoimmun Rev"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/rheumatology\/keg153","article-title":"Presentation and management of idiopathic inflammatory muscle disease: four case reports and commentary from a series of 78 patients","volume":"42","author":"Kiely","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"102426","DOI":"10.1016\/j.autrev.2019.102426","article-title":"Subcutaneous immunoglobulin in inflammatory myopathies: efficacy in different organ systems","volume":"19","author":"Danieli","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"e19012","DOI":"10.1097\/MD.0000000000019012","article-title":"Recovering autonomy is a key advantage of home-based immunoglobulin therapy in patients with myositis: a qualitative research study","volume":"99","author":"Ch\u00e9rin","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/rheumatology\/key450","article-title":"Efficacy and safety of rituximab in antisynthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study","volume":"58","author":"Leclair","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/rheumatology\/kew146","article-title":"Rituximab in the treatment of inflammatory myopathies: a review","volume":"56","author":"Fasano","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/sarh.2002.50012","article-title":"Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment","volume":"32","author":"Schnabel","year":"2003","journal-title":"Semin Arthritis Rheum"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00296-018-3991-7","article-title":"Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review","volume":"38","author":"Gonzalez-Moreno","year":"2018","journal-title":"Rheumatol Int"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1684\/ejd.2019.3634","article-title":"Clinical features and poor prognostic factors of antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease","volume":"29","author":"Motegi","year":"2019","journal-title":"Eur J Dermatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T03:15:25Z","timestamp":1693278925000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000745","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]}}}